阅读说明：本技术 Il17rb基因人源化的非人动物的构建方法及应用 (Construction method and application of IL17RB gene humanized non-human animal ) 是由 赵磊 刘畅 于 2021-02-05 设计创作，主要内容包括：本发明提供了一种IL17RB基因人源化的非人动物的构建方法,利用同源重组的方式将编码人IL17RB蛋白的核苷酸序列导入非人动物基因组中,该动物体内能正常表达人源化IL17RB蛋白,可以作为人IL17RB信号机理研究、肿瘤及免疫性疾病药物筛选的动物模型,对免疫靶点的新药研发具有重要的应用价值。本发明还提供了一种人源化IL17RB蛋白、一种人源化IL17RB基因、一种IL17RB基因的靶向载体,以及上述构建方法获得的非人动物及其在生物医药领域的应用。(The invention provides a construction method of a non-human animal humanized with IL17RB gene, which utilizes a homologous recombination mode to introduce a nucleotide sequence coding human IL17RB protein into the genome of the non-human animal, and the animal can normally express humanized IL17RB protein, can be used as an animal model for researching the signal mechanism of human IL17RB and screening tumor and immune disease drugs, and has important application value for the research and development of new drugs of immune targets. The invention also provides a humanized IL17RB protein, a humanized IL17RB gene and a targeting vector of the IL17RB gene, a non-human animal obtained by the construction method and application thereof in the field of biomedicine.)

1. A method of constructing a non-human animal humanized with the IL17RB gene, comprising administering to a human animal a peptide comprising a sequence encoding SEQ ID NO: 2, position 22-287 into the non-human animal IL17RB locus.

2. The method of claim 1, comprising administering a peptide comprising SEQ ID NO: 5 to the non-human animal IL17RB locus.

3. The construct of claim 1 or 2, wherein the replacement to the non-human animal IL17RB locus is a replacement of the nucleotide sequence of the non-human animal IL17RB gene encoding SEQ ID NO: 1, 22-284, or a nucleotide sequence identical to the sequence shown in positions 29720048-29728828 of NCBI accession No. NC _000080.7, in place of a non-human animal, which is a mouse or rat.

4. The method of claim 1 or 2, wherein the non-human animal expresses a humanized IL17RB protein with reduced or absent expression of endogenous IL17RB protein, and wherein the humanized IL17RB protein comprises the amino acid sequence of SEQ ID NO: 10, or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 or 2, wherein the genome of the non-human animal comprises a humanized IL17RB gene, and the mRNA transcribed from the humanized IL17RB gene comprises SEQ ID NO: 9, or a nucleotide sequence shown in the specification.

6. The method of claim 1 or 2, wherein the non-human animal is constructed using a targeting vector comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 or a nucleotide sequence comprising SEQ ID NO: 5, and the targeting vector further comprises a 5 ' arm and/or a 3 ' arm, and the nucleotide sequence of the 5 ' arm is shown as SEQ ID NO: 3, and the nucleotide sequence of the 3' arm is shown as SEQ ID NO: 4, respectively.

7. A targeting vector of IL17RB gene, which is characterized in that the targeting vector comprises a nucleotide sequence encoding SEQ ID NO: 2 or a nucleotide sequence comprising SEQ ID NO: 5, and the targeting vector further comprises a 5 ' arm and/or a 3 ' arm, and the nucleotide sequence of the 5 ' arm is shown as SEQ ID NO: 3, and the nucleotide sequence of the 3' arm is shown as SEQ ID NO: 4, respectively.

8. A humanized IL17RB protein, wherein the amino acid sequence of the humanized IL17RB protein is shown as SEQ ID NO: shown at 10.

9. A humanized IL17RB gene encoding the humanized IL17RB protein of claim 8, wherein the humanized IL17RB gene comprises the amino acid sequence of SEQ ID NO: 5.

10. Use of a non-human animal humanized with the IL17RB gene obtained by the construction method according to any one of claims 1 to 6, the humanized IL17RB protein according to claim 8 or the humanized IL17RB gene according to claim 9 for non-disease diagnostic, non-disease therapeutic purposes, the use comprising:

A) use in the development of products involving the immune processes associated with IL17RB in human cells;

B) use as model system in pharmacological, immunological, microbiological and medical research in relation to IL17 RB;

C) to the production and use of animal experimental disease models for the study of the etiology associated with IL17RB and/or for the development of diagnostic strategies and/or for the development of therapeutic strategies;

D) the application of the IL17RB signal channel regulator in screening, drug effect detection, curative effect evaluation, verification or evaluation in vivo; alternatively, the first and second electrodes may be,

E) the application of the gene function of IL17RB, the medicine and the drug effect aiming at the target site of human IL17RB, the medicine for treating the immune-related diseases related to IL17RB and the anti-tumor medicine are researched.

Technical Field

The invention belongs to the field of animal genetic engineering and genetic modification, and particularly relates to a construction method of an IL17RB gene modified non-human animal model and application thereof in the field of biomedicine.

Background

The Interleukin (IL) 17 cytokine (abbreviated as IL 17) family is a characteristic cytokine, which is secreted mainly by activated Th17 cells. The IL17 family has now found 6 members, IL17A, IL17B, IL17C, IL17D, IL17E and IL17F, respectively. The IL17 receptor (abbreviated as IL 17R) also forms a unique family, and 5 homologous subunits are found at present, namely IL17RA, IL17RB, IL17RC, IL17RD and IL17 RE. IL17, by binding to the receptor, initiates its downstream signaling pathways (including the MAP kinase pathway, NF-kB pathway, mRNA stabilization signaling pathway, ERK signaling pathway, and JAK/STAT signaling pathway, etc.), stimulates the production of inflammatory mediators by a variety of cells, has become a key contributor to immune and inflammatory diseases, and can lead to organ-specific or systemic autoimmune diseases.

IL17RB is expressed on the surface of many organs and tissues in the body, and is involved in innate and adaptive immune responses by binding to IL17B and IL17E, activating Jun kinase (JNK), p38 mitogen-activated protein kinase (p 38 MAPK) and nuclear factor-kappa B (NF-kappa B), eosinophil products such as monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1 alpha), IL6 and IL 8. In recent years, it has been found that IL17RB is closely related to tumors (e.g., breast cancer, gastric cancer, pancreatic cancer, etc.) and autoimmune diseases (e.g., asthma, allergic rhinitis, etc.). For example, IL-17RB can mediate anti-apoptosis through NF-kB pathway, promoting the occurrence of breast tumor; the expression level of the IL17RB protein in the gastric cancer tissue is higher than that of the tissue beside the cancer, and the protein plays a certain role in the generation and development of the gastric cancer; the growth of pancreatic cancer can be effectively inhibited by using IL17RB neutralizing antibody; IL17RB is up-regulated in expression levels in the intestinal inflammatory response; genetic variation of IL17RB may play an important role in Th 2-mediated immune responses to asthma.

The experimental animal disease model is an indispensable research tool for researching etiology and pathogenesis of human diseases, developing prevention and treatment technologies and developing medicines. However, due to the differences between the physiological structures and metabolic systems of animals and humans, the traditional animal models cannot reflect the real conditions of human bodies well, and the establishment of disease models closer to the physiological characteristics of human bodies in animal bodies is an urgent need of the biomedical industry. With the continuous development and maturation of genetic engineering technology, the replacement or substitution of animal homologous genes with human genes has been realized, and the development of humanized experimental animal models in this way is the future development direction of animal models. The gene humanized animal model is one animal model with normal or mutant gene replaced with homologous gene in animal genome and similar physiological or disease characteristics. The gene humanized animal not only has important application value, for example, the humanized animal model of cell or tissue transplantation can be improved and promoted by gene humanization, but also more importantly, the human protein can be expressed or partially expressed in the animal body due to the insertion of the human gene segment, and the gene humanized animal can be used as a target of a drug which can only recognize the human protein sequence, thereby providing possibility for screening anti-human antibodies and other drugs at the animal level. However, the production of humanized animal models can be successfully achieved without any gene or by replacing any region of any gene. In this field, it is also most important and most challenging to obtain a humanized animal model that can express a humanized protein and has functions such as antibody screening by inserting or replacing a specific sequence of a specific non-human animal gene and a specific region of a corresponding human gene according to actual needs.

Therefore, due to differences in physiology and pathology between animals and humans, coupled with the complexity of the IL17RB gene, how to construct an "effective" humanized animal model of IL17RB for new drug development remains the greatest challenge.

Disclosure of Invention

In view of the complex action mechanism of each ligand and receptor of IL17/IL17R and the great application value in the field of tumor and autoimmune disease treatment, in order to further explore the relevant biological characteristics, improve the effectiveness of the preclinical pharmacodynamic test, improve the research and development success rate, enable the preclinical test to be more effective and minimize the research and development failure, the field urgently needs to develop more non-human animal models of IL17/IL17R relevant signal pathways. In addition, the non-human animal obtained by the method can be mated with other gene humanized non-human animals to obtain a multi-gene humanized animal model which is used for screening and evaluating the drug effect research of human drugs and combined drugs aiming at the signal path. The invention has wide application prospect in academic and clinical research. In particular, the method comprises the following steps of,

in the first aspect of the invention, a method for constructing a non-human animal humanized with an IL17RB gene is provided, wherein the genome of the non-human animal comprises all or part of a human IL17RB gene. Preferably, all or part of exon 1 to exon 11 of the human IL17RB gene is comprised. Further preferably, the recombinant human IL17RB comprises any one or a combination of two or more of exons 1 to 11 of the gene. Still more preferably, it comprises exon 2 to exon 10 of the human IL17RB gene.

In a specific embodiment of the present invention, the genome of said non-human animal comprises part of exon 2, all of exons 3 to 9 and part of exon 10 of human IL17RB gene, preferably further comprises intron 2-3 and/or intron 9-10. Wherein, the part of the No. 2 exon at least comprises the nucleotide sequence with the length of 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp or 25bp from the No. 2 exon 3 '-5', and the part of the No. 10 exon at least comprises the nucleotide sequence with the length of 10bp, 11, 12, 13, 14, 15bp, 20bp, 30bp or 40bp from the No. 10 exon 5 '-3'.

Preferably, the non-human animal comprises a humanized IL17RB gene. The humanized IL17RB gene comprises all or part of human IL17RB gene. Preferably part of exon 2, all of exons 3 to 9 and part of exon 10 of the human IL17RB gene, preferably further comprising intron 2-3 and/or intron 9-10.

Preferably, the method of construction comprises insertion or substitution into the non-human animal IL17RB locus with a construct comprising all or part of exon 1 to exon 11 of the human IL17RB gene. Further preferred, comprises insertion or substitution into the non-human animal IL17RB locus with a composition comprising any one or two or more of exons 1 to 11 of the human IL17RB gene. Even more preferably, the method comprises inserting or replacing exon 2 to exon 10 comprising the human IL17RB gene into the non-human animal IL17RB locus.

In one embodiment of the invention, the construction method comprises inserting or replacing a portion of exon 2, all of exons 3 to 9, and a portion of exon 10, preferably further comprising intron 2-3 and/or intron 9-10 of human IL17RB into the non-human animal IL17RB locus.

In one embodiment of the invention, the method of construction comprises insertion or substitution of a nucleotide sequence comprising a humanized IL17RB gene into the non-human animal IL17RB locus.

In a second aspect of the invention, there is provided a method of constructing a non-human animal in which the IL17RB gene is humanized, wherein the non-human animal expresses a human or humanized IL17RB protein.

The humanized IL17RB protein comprises all or part of a human IL17RB protein. Preferably, the humanized IL17RB protein comprises all or part of the extracellular domain of human IL17RB protein. Further preferably, the humanized IL17RB protein further comprises a signal peptide, a transmembrane region and/or a cytoplasmic region of the human IL17RB protein.

Preferably, the humanized IL17RB protein comprises at least 200 amino acids, e.g., at least 200, 210, 220, 230, 240, 250, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 280, 285 amino acids of the extracellular region of the human IL17RB protein, and preferably the humanized IL17RB protein comprises 266 amino acids of the extracellular region of the human IL17RB protein.

In one embodiment of the present invention, the humanized IL17RB protein comprises the extracellular domain of human IL17RB protein from 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acids from the N-terminus to 1-15 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) amino acids from the C-terminus.

Preferably, the construction method comprises inserting or replacing the non-human animal IL17RB locus with a nucleotide sequence comprising an extracellular region encoding human IL17RB protein. Further preferably, the construction method comprises inserting or replacing the nucleotide sequence encoding the extracellular domain of human IL17RB from amino acids 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) from the N-terminal to amino acids 1-15 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) from the C-terminal into the non-human animal IL17RB locus.

Preferably, the method of construction comprises insertion or substitution into the non-human animal IL17RB locus with a nucleotide sequence comprising a protein encoding humanized IL17 RB.

In a third aspect of the present invention, there is provided a method of constructing a non-human animal humanized with the IL17RB gene, said method comprising administering to said animal a peptide comprising the sequence encoding SEQ ID NO: 2, position 22-287 into the non-human animal IL17RB locus.

Preferably, the method of construction comprises the use of a polynucleotide comprising SEQ ID NO: 5 to the non-human animal IL17RB locus.

Preferably, the site of insertion or replacement is after the endogenous regulatory elements.

Preferably, the insertion firstly disrupts the coding frame of the endogenous IL17RB gene of the non-human animal or the insertion step can achieve the aim of preventing the coding frame of the endogenous IL17RB gene from being expressed.

Preferably, the replacement is a replacement of a corresponding position.

Preferably, said replacement at the non-human animal IL17RB locus is a replacement of the amino acid sequence of the non-human animal IL17RB gene encoding SEQ ID NO: 1 from position 22 to 284 or a nucleotide sequence which replaces the non-human animal with a nucleotide sequence which is identical to the sequence shown at positions 29720048 to 29728828 of NCBI accession No. NC _ 000080.7.

The non-human animal is a mouse or a rat.

Preferably, the non-human animal body expresses a human or humanized IL17RB protein. Preferably, the humanized IL17RB protein comprises SEQ ID NO: 2, amino acid sequence from position 22 to 287.

Preferably, the expression of endogenous IL17RB protein in the non-human animal is reduced or deleted.

In a specific embodiment of the invention, said humanized IL17RB protein comprises the amino acid sequence of SEQ ID NO: 10, or comprises an amino acid sequence identical to SEQ ID NO: 10, or an amino acid sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to SEQ ID NO: 10 by NO more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or NO more than 1 amino acid difference, or, alternatively, comprises a sequence having the amino acid sequence of SEQ ID NO: 10 comprising substitution, deletion and/or insertion of one or more amino acid residues.

Preferably, the genome of the non-human animal comprises a humanized IL17RB gene. The humanized IL17RB gene comprises SEQ ID NO: 5.

In one embodiment of the invention, the mRNA transcribed from the humanized IL17RB gene comprises SEQ ID NO: 9, or a nucleotide sequence identical to SEQ ID NO: 9, or a nucleotide sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to the nucleotide sequence set forth in SEQ ID NO: 9 by NO more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or NO more than 1 nucleotide, or alternatively, a nucleic acid sequence comprising a nucleotide sequence having the sequence of SEQ ID NO: 9, including nucleotide sequences with one or more nucleotides substituted, deleted and/or inserted.

Preferably, the human IL17RB gene, humanized IL17RB gene, humanized IL17RB protein or nucleotide sequence encoding human IL17RB protein is regulated by IL17RB endogenous regulatory elements.

The invention uses gene editing technology to construct non-human animals with humanized IL17RB gene, wherein the gene editing technology comprises gene targeting technology using embryonic stem cells, CRISPR/Cas9 technology, zinc finger nuclease technology, transcription activator-like effector nuclease technology, homing endonuclease or other molecular biology technology.

In one embodiment of the invention, the construction of the non-human animal is performed using a targeting vector.

The targeting vector comprises all or part of the human IL17RB gene. Preferably, all or part of exon 1 to exon 11 of the human IL17RB gene is comprised. Further preferably, the recombinant human IL17RB comprises any one or a combination of two or more of exons 1 to 11 of the gene. Still more preferably, it comprises exon 2 to exon 10 of the human IL17RB gene. Still further preferably, the genome of said non-human animal comprises part of exon 2, all of exons 3 to 9 and part of exon 10 of human IL17RB gene, preferably further comprises intron 2-3 and/or intron 9-10. Wherein, the part of the No. 2 exon at least comprises the nucleotide sequence with the length of 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp or 25bp from the No. 2 exon 3 '-5', and the part of the No. 10 exon at least comprises the nucleotide sequence with the length of 10bp, 11, 12, 13, 14, 15bp, 20bp, 30bp or 40bp from the No. 10 exon 5 '-3'.

In one embodiment of the invention, the targeting vector comprises a nucleic acid sequence encoding SEQ ID NO: 2 or a nucleotide sequence comprising SEQ ID NO: 5.

The targeting vector further comprises a 5 'arm and/or a 3' arm.

Wherein the 5 'arm is a DNA fragment homologous to the 5' end of the transition region to be altered. Preferably, it is selected from nucleotides having at least 90% homology with NCBI accession No. NC _ 000080.7. More preferably, it is 3000-4500bp in length.

In one embodiment of the invention, the nucleotide sequence of the 5' arm is as set forth in SEQ ID NO: 3, respectively.

The 3 'arm is a DNA fragment homologous to the 3' end of the transition region to be altered. Preferably, it is selected from nucleotides having at least 90% homology with NCBI accession No. NC _ 000080.7. Further preferably, the length is 4000-.

In one embodiment of the invention, the nucleotide sequence of the 3' arm is as set forth in SEQ ID NO: 4, respectively.

Preferably, the transition region to be altered is located in exon 2 to exon 10 of the non-human animal IL17RB gene.

In a specific embodiment of the invention, the construction method comprises introducing the targeting vector into a cell of a non-human animal, culturing the cell (preferably an embryonic stem cell), transplanting the cultured cell into an oviduct of a female non-human animal, allowing the female non-human animal to develop, and identifying and screening the non-human animal humanized with the IL17RB gene.

Preferably, to improve recombination efficiency, a non-human animal can also be constructed using sgRNA targeting IL17RB gene together with the above-described targeting vector. Wherein the sgRNA targets the non-human animal IL17RB gene, while the sequence of the sgRNA is on the target sequence on the IL17RB gene to be altered. Preferably, the target site of the sgRNA is located on exon 2 and/or exon 10 of the IL17RB gene.

In a fourth aspect of the present invention, there is provided a non-human animal humanized with IL17RB gene obtained by the above-mentioned construction method.

In the fifth aspect of the invention, a construction method of a non-human animal with a deleted IL17RB gene is provided, and the construction method comprises knocking out all or part of exons 1 to 11 of an endogenous IL17RB gene. Preferably, any one or a combination of two or more of exons 1 to 11 is knocked out. Further preferred comprises exons No. 2 to 10.

In one embodiment of the present invention, a portion of exon 2, all of exons 3 to 9, and a portion of exon 10 are included, preferably further including intron 2-3 and/or intron 9-10.

In a sixth aspect of the present invention, there is provided a non-human animal obtained by the above-described construction method, in which the IL17RB gene is deleted.

In a seventh aspect of the invention, a targeting vector for IL17RB gene is provided, wherein the targeting vector comprises all or part of human IL17RB gene. Preferably, all or part of exon 1 to exon 11 of the human IL17RB gene is comprised. Further preferably, the recombinant human IL17RB comprises any one or a combination of two or more of exons 1 to 11 of the gene. Still more preferably, it comprises exon 2 to exon 10 of the human IL17RB gene. Still further preferably, the genome of said non-human animal comprises part of exon 2, all of exons 3 to 9 and part of exon 10 of human IL17RB gene, preferably further comprises intron 2-3 and/or intron 9-10. Wherein, the part of the No. 2 exon at least comprises the nucleotide sequence with the length of 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp or 25bp from the No. 2 exon 3 '-5', and the part of the No. 10 exon at least comprises the nucleotide sequence with the length of 10bp, 11, 12, 13, 14, 15bp, 20bp, 30bp or 40bp from the No. 10 exon 5 '-3'.

In one embodiment of the invention, the targeting vector comprises a nucleic acid sequence encoding SEQ ID NO: 2 or a nucleotide sequence comprising SEQ ID NO: 5.

The targeting vector further comprises a 5 'arm and/or a 3' arm.

Wherein the 5 'arm is a DNA fragment homologous to the 5' end of the transition region to be altered. Preferably, it is selected from nucleotides having at least 90% homology with NCBI accession No. NC _ 000080.7. More preferably, it is 3000-4500bp in length.

In one embodiment of the invention, the nucleotide sequence of the 5' arm is as set forth in SEQ ID NO: 3, respectively.

The 3 'arm is a DNA fragment homologous to the 3' end of the transition region to be altered. Preferably, it is selected from nucleotides having at least 90% homology with NCBI accession No. NC _ 000080.7. Further preferably, the length is 4000-.

In one embodiment of the invention, the nucleotide sequence of the 3' arm is as set forth in SEQ ID NO: 4, respectively.

Preferably, the transition region to be altered is located in exon 2 to exon 10 of the non-human animal IL17RB gene.

Preferably, the targeting vector further comprises a selectable gene marker.

Preferably, the marker gene is a gene encoding a negative selection marker. Further preferably, the gene encoding the negative selection marker is a gene encoding diphtheria toxin subunit a (DTA).

Preferably, the targeting vector further comprises a resistance gene for positive clone selection. Further preferably, the resistance gene selected by the positive clone is neomycin phosphotransferase coding sequence Neo.

Preferably, the targeting vector further comprises a specific recombination system. Further preferably, the specific recombination system is a Frt recombination site (a conventional LoxP recombination system can also be selected). The number of the specific recombination systems is 2, and the specific recombination systems are respectively arranged at two sides of the resistance genes.

In an eighth aspect of the invention, there is provided a cell comprising the targeting vector described above.

In a ninth aspect of the invention, there is provided a use of the targeting vector or the cell comprising the targeting vector in IL17RB gene modification.

In the tenth aspect of the present invention, there is provided a humanized IL17RB protein, wherein the humanized IL17RB protein comprises all or part of human IL17RB protein.

Preferably, the humanized IL17RB protein comprises all or part of the extracellular domain of human IL17RB protein. Further preferably, the humanized IL17RB protein further comprises a signal peptide, a transmembrane region and/or a cytoplasmic region of the human IL17RB protein.

Preferably, the humanized IL17RB protein comprises at least 200 amino acids, e.g., at least 200, 210, 220, 230, 240, 250, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 280, 285 amino acids of the extracellular region of the human IL17RB protein, and preferably the humanized IL17RB protein comprises 266 amino acids of the extracellular region of the human IL17RB protein.

In one embodiment of the present invention, the humanized IL17RB protein comprises the extracellular domain of human IL17RB protein from 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acids from the N-terminus to 1-15 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) amino acids from the C-terminus.

Preferably, the humanized IL17RB protein comprises an amino acid sequence encoded by exon 2 to exon 10 of human IL17RB gene. Further preferred is an amino acid sequence encoded by a portion of exon 2, all of exons 3 to 9, and a portion of exon 10 of the human IL17RB gene.

Preferably, the humanized IL17RB protein comprises SEQ ID NO: 2, amino acid sequence 22-287.

In one embodiment of the present invention, the amino acid sequence of the humanized IL17RB protein is as set forth in SEQ ID NO: 10, or, alternatively, a variant of SEQ ID NO: 10, or an amino acid sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to SEQ ID NO: 10 by NO more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or NO more than 1 amino acid difference, or an amino acid sequence having the amino acid sequence shown in SEQ ID NO: 10 comprising substitution, deletion and/or insertion of one or more amino acid residues.

In an eleventh aspect of the present invention, there is provided a humanized IL17RB gene encoding the above humanized IL17RB protein. Preferably, the humanized IL17RB gene comprises all or part of the human IL17RB gene. Further, it preferably contains any one of exons 1 to 11 of human IL17RB gene or a combination of two or more thereof. Still more preferably, the humanized IL17RB gene comprises part of exon 2, all of exons 3 to 9 and part of exon 10 of human IL17 RB.

Preferably, the humanized IL17RB gene comprises SEQ ID NO: 5.

In one embodiment of the invention, the mRNA transcribed from the humanized IL17RB gene comprises SEQ ID NO: 9, or a nucleotide sequence identical to SEQ ID NO: 9, or a nucleotide sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identity to the nucleotide sequence set forth in SEQ ID NO: 9 by NO more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or NO more than 1 nucleotide, or alternatively, a nucleic acid sequence comprising a nucleotide sequence having the sequence of SEQ ID NO: shown at 9.

In a twelfth aspect of the invention, there is provided a construct expressing the above humanized IL17RB protein. Preferably, the construct comprises the above-described humanized IL17RB gene.

In a thirteenth aspect of the invention, there is provided a cell comprising the above construct.

In a fourteenth aspect of the invention, there is provided a tissue comprising the above-described cells.

In a fifteenth aspect of the present invention, there is provided a method for constructing a polygene-modified non-human animal, said method comprising:

(a) preparing and obtaining the non-human animal by applying the construction method;

(b) mating the non-human animal obtained in step (a) with a genetically modified animal other than IL17RB, inseminating in vitro or directly performing gene editing, and screening to obtain a polygenic humanized modified non-human animal.

Preferably, the multi-gene humanized modified non-human animal is a two-gene humanized non-human animal, a three-gene humanized non-human animal, a four-gene humanized non-human animal, a five-gene humanized non-human animal, a six-gene humanized non-human animal, a seven-gene humanized non-human animal, an eight-gene humanized non-human animal or a nine-gene humanized non-human animal.

Preferably, the animals modified by genes other than IL17RB are selected from one or more than two of the animals modified by genes PD-1, PD-L1, IL17A, IL17F, IL17RA or IL17 RC.

In a sixteenth aspect of the invention, a tumor-bearing animal model is provided, and the preparation method of the animal model comprises the step of preparing animals by the construction method.

Preferably, the method for preparing the tumor-bearing animal model further comprises the step of implanting tumor cells into the non-human animal prepared by the above method or its offspring.

In a seventeenth aspect of the present invention, there is provided a cell, tissue or organ modified with IL17RB gene, which is obtained by the above-mentioned method for constructing a non-human animal humanized with IL17RB gene or a method for constructing a multi-gene modified non-human animal, or which is derived from the above-mentioned non-human animal humanized with IL17RB gene or the above-mentioned multi-gene modified non-human animal, or the above-mentioned tumor-bearing animal model.

The eighteenth aspect of the present invention provides a non-human animal humanized with IL17RB gene obtained by the above construction method, the above humanized IL17RB protein or the above humanized IL17RB gene, and applications thereof for non-disease diagnosis and non-disease treatment purposes, the applications comprising:

A) use in the development of products involving the immune processes associated with IL17RB in human cells;

B) use as model system in pharmacological, immunological, microbiological and medical research in relation to IL17 RB;

C) to the production and use of animal experimental disease models for the study of the etiology associated with IL17RB and/or for the development of diagnostic strategies and/or for the development of therapeutic strategies;

D) the application of the IL17RB signal channel regulator in screening, drug effect detection, curative effect evaluation, verification or evaluation in vivo; alternatively, the first and second electrodes may be,

E) the application of the gene function of IL17RB, the medicine and the drug effect aiming at the target site of human IL17RB, the medicine for treating the immune-related diseases related to IL17RB and the anti-tumor medicine are researched.

The nineteenth aspect of the present invention provides a humanized non-human animal of IL17RB gene obtained by the above-mentioned construction method, a non-human animal with IL17RB gene deleted obtained by the above-mentioned construction method, a multi-gene modified non-human animal obtained by the above-mentioned construction method, and an application of the above-mentioned tumor-bearing animal model in the preparation of a medicament for treating or preventing tumor, immune-related disease or inflammation.

The "tumor" according to the present invention includes, but is not limited to, lymphoma, brain cancer, non-small cell lung cancer, cervical cancer, esophageal cancer, leukemia, ovarian cancer, nasopharyngeal cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, stomach cancer, bladder cancer, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreatic cancer, liver and bile duct cancer, esophageal cancer, kidney cancer, thyroid cancer, head and neck cancer, testicular cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, and sarcoma. Wherein the leukemia is selected from acute lymphocytic (lymphoblastic) leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, multiple myeloma, plasma cell leukemia, and chronic myelogenous leukemia; said lymphoma is selected from Hodgkin's lymphoma and non-Hodgkin's lymphoma, including B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, T-cell lymphoma, and Waldenstrom's macroglobulinemia; the sarcoma is selected from osteosarcoma, Ewing's sarcoma, leiomyosarcoma, synovial sarcoma, soft tissue sarcoma, angiosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma, and chondrosarcoma.

In one embodiment of the invention, the tumor is selected from breast cancer, gastric cancer or pancreatic cancer.

The "immune-related diseases" described in the present invention include, but are not limited to, allergy, asthma, dermatitis, myocarditis, nephritis, hepatitis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain, or neurological disorder, etc.

The "cell" of the present invention may be any cell of animal or human origin, including but not limited to lymphocytes, monocytes, macrophages, endothelial cells, epithelial cells, CD34+ thymocytes, neurons or tumor cells.

The humanized IL17RB protein comprises a part derived from human IL17RB protein and a part of non-human animal IL17RB protein.

The "humanized IL17RB gene" of the present invention comprises a part derived from human IL17RB gene and a part of non-human animal IL17RB gene.

The term "comprising" or "comprises" as used herein is open-ended, and when used in this application to describe a sequence of a protein or nucleic acid, the protein or nucleic acid may be comprised of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still possess the activity described herein.

The "exon" from xx to xx or the "exon from xx to xx" in the present invention includes exons and introns therebetween. For example, "exon nos. 3 to 9" comprises the nucleotide sequence of exon nos. 3, intron nos. 3 to 4, exon nos. 4, intron nos. 4 to 5, exon nos. 5, intron nos. 5 to 6, exon nos. 6, intron nos. 6 to 7, exon nos. 7, intron nos. 7 to 8, exon nos. 8, intron nos. 8 to 9 and exon nos. 9.

The term "intron" used herein means an intron from exon x to exon xx. For example, "intron 2-3" means an intron between exon 2 and exon 3.

The "locus" of the present invention refers to the position of a gene on a chromosome in a broad sense and refers to a DNA fragment of a certain gene in a narrow sense, and the gene may be a single gene or a part of a single gene. For example, the "IL 17RB locus" refers to a DNA fragment of an optional stretch of the IL17RB gene. In one embodiment of the invention, the replaced IL17RB locus may be a DNA fragment of any one of exons 2 to 10 of IL17RB gene.

The "nucleotide sequence" of the present invention includes a natural or modified ribonucleotide sequence and a deoxyribonucleotide sequence. Preferably DNA, cDNA, pre-mRNA, rRNA, hnRNA, miRNAs, scRNA, snRNA, siRNA, sgRNA, tRNA.

The term "treating" (or "treatment") as used herein means slowing, interrupting, arresting, controlling, stopping, alleviating, or reversing the progression or severity of one sign, symptom, disorder, condition, or disease, but does not necessarily refer to the complete elimination of all disease-related signs, symptoms, conditions, or disorders. The term "treatment" or the like refers to a therapeutic intervention that ameliorates the signs, symptoms, etc. of a disease or pathological state after the disease has begun to develop.

The term "homology" as used herein refers to the fact that, in the aspect of using an amino acid sequence or a nucleotide sequence, a person skilled in the art can adjust the sequence according to the actual working requirement, so that the used sequence has (including but not limited to) 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identity.

One skilled in the art can determine and compare sequence elements or degrees of identity to distinguish between additional mouse and human sequences.

In one aspect, the non-human animal is a mammal, preferably any non-human mammal that can be genetically engineered to make a gene humanized, such as a rodent, pig, rabbit, monkey. In one aspect, the non-human animal is a small mammal, such as a rhabdoid. In one embodiment, the non-human animal to which the gene is humanized is a rodent. In one embodiment, the rodent is selected from a mouse, a rat, and a hamster. In one embodiment, the rodent is selected from the murine family. In one embodiment, the genetically modified animal is from the family of cricotidae (e.g., mouse-like hamsters), cricotidae (e.g., hamsters, new world rats and mice, voles), muridae (true mice and rats, gerbils, spiny mice, crow rats), marmoraceae (mountaineers, rock mice, tailed rats, madagaska rats and mice), spiny muridae (e.g., spiny mice), and spale (e.g., mole rats, bamboo rats, and zokors). In a particular embodiment, the genetically modified rodent is selected from a true mouse or rat (superfamily murinus), a gerbil, a spiny mouse, and a crowned rat. In one embodiment, the genetically modified mouse is from a member of the murine family. In one embodiment, the animal is a rodent. In a particular embodiment, the rodent is selected from a mouse and a rat. In one embodiment, the non-human animal is a mouse.

In a particular embodiment, the non-human animal is a rodent, a strain of C57BL, C58, a/Br, CBA/Ca, CBA/J, CBA/CBA/mouse selected from BALB/C, a/He, a/J, A/WySN, AKR/A, AKR/J, AKR/N, TA1, TA2, RF, SWR, C3H, C57BR, SJL, C57L, DBA/2, KM, NIH, ICR, CFW, FACA, C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10 sn, C57BL/10Cr and C57 BL/Ola.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology. These techniques are explained in detail in the following documents. For example: molecular Cloning A Laboratory Manual, 2nd Ed., ed. By Sambrook, FritschandManiatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (d.n. glovered., 1985); oligonucleotide Synthesis (m.j. gaited., 1984); mullisetal U.S. Pat. No.4, 683, 195; nucleic Acid Hybridization (B.D. Hames & S.J. Higgins.1984); transformation And transformation (B.D. Hames & S.J. Higgins.1984); culture Of Animal Cells (r.i. freshney, alanr.liss, inc., 1987); immobilized Cells And Enzymes (IRL Press, 1986); B.Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J.Abelson and M.Simon, eds., In-chief, Academic Press, Inc., New York), specific, volumes, 154 and 155 (Wuetal. eds.) and Vol.185, "Gene Expression Technology" (D.Goeddel, ed.); gene Transfer Vectors For Mammarian Cells (J.H.Miller and M.P.Caloseds, 1987, Cold Spring Harbor Laboratory); immunochemical Methods In Cell And Molecular Biology (Mayer And Walker, eds., Academic Press, London, 1987); handbook Of Experimental Immunology, Volumes V (d.m.weir and c.c.blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

The foregoing is merely a summary of aspects of the invention and is not, and should not be taken as, limiting the invention in any way.

All patents and publications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication was specifically and individually indicated to be incorporated herein by reference. Those skilled in the art will recognize that certain changes may be made to the invention without departing from the spirit or scope of the invention.

The following examples further illustrate the invention in detail and are not to be construed as limiting the scope of the invention or the particular methods described herein.

Drawings

Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:

FIG. 1: schematic comparison of mouse IL17RB gene and human IL17RB locus (not to scale).

FIG. 2: schematic representation (not to scale) of humanization of the mouse IL17RB gene.

FIG. 3: IL17RB gene targeting strategy and targeting vector design schematic (not to scale).

FIG. 4: cellular Southern blot results after IL17RB recombination, where WT was the wild type control.

FIG. 5: FRT recombination process schematic (not to scale) for humanized mouse IL17RB gene.

FIG. 6: IL17RB gene humanized mouse F1 mouse tail PCR identification result, wherein, WT is wild type, H₂O is water control and PC is positive control.

FIG. 7: detection results of IL17RB mRNA in thymus tissues of C57BL/6 wild type mice (WT) and IL17RB gene humanized homozygote mice (IL 17 RB), wherein M is Marker, H₂O is water control and WT is wildAnd (4) a birth control.

Detailed Description

The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.

In each of the following examples, the equipment and materials were obtained from several companies as indicated below:

AseI, NdeI and BamHI enzymes are purchased from NEB, and the cargo numbers are R0526M, R0111S and R0136M respectively;

c57BL/6 mice and Flp tool mice were purchased from the national rodent experimental animal seed center of the Chinese food and drug assay institute;

PrimeScript 1st strand cDNA Synthesis Kit purchased from TAKARA, cat # 6110A;

TRIzol. Reagent is purchased from Invitrogen, cat # 15596018;

zombie NIR "Fixable visualization Kit from Biolegend, cat # B24952;

the RNAprep pure culture cell/bacteria total RNA extraction kit is purchased from Tiangen, a commodity number DP 430;

attune Nxt Acoustic Focusing Cytometer was purchased from Thermo Fisher, model Attune Nxt;

heraeus ™ Fresco ™ 21 Microcentifuge from Thermo Fisher, model Fresco 21;

BioTek Epoch Microplate Reader is available from BioTeK, model EPOCH.

Example 1 IL17RB Gene humanized mice

A schematic comparison of the mouse IL17RB Gene (NCBI Gene ID: 50905, Primary source: MGI: 1355292, UniProt: Q9JIP3, from position 29718125 to 29730853 on chromosome 14 NC-000080.7, based on transcript NM-019583.3 and its encoded protein NP-062529.2 (SEQ ID NO: 1)) and the human IL17RB Gene (NCBI Gene ID: 55540, Primary source: HGNC:18015, UniProt ID: Q9NRM6, from position 53846550 to 53867388 on chromosome 3 NC-000003.12, based on transcript NM-018725.4 and its encoded protein NP-061195.2 (SEQ ID NO: 2)) is shown in FIG. 1.

To achieve the object of the present invention, a nucleotide sequence encoding human IL17RB protein may be introduced at the endogenous IL17RB locus of a mouse, so that the mouse expresses human or humanized IL17RB protein. Specifically, the gene editing technology is used for replacing a part sequence from a part sequence of a mouse exon 2 to a part sequence of a mouse exon 10 by a part sequence from a exon 2 to a exon 10 containing the human IL17RB gene under the control of a mouse IL17RB gene regulatory element to obtain a humanized IL17RB locus schematic diagram as shown in FIG. 2, so that the humanized transformation of the mouse IL17RB gene is realized.

The targeting strategy was designed as shown in FIG. 3, which shows the homology arm sequences on the targeting vector containing the upstream and downstream of the mouse IL17RB gene, as well as an A fragment containing the sequence of human IL17 RB. Wherein, the upstream homology arm sequence (5 'homology arm, SEQ ID NO: 3) is identical to the nucleotide sequence from position 29728829 to 29732752 of NCBI accession No. NC-000080.7, and the downstream homology arm sequence (3' homology arm, SEQ ID NO: 4) is identical to the nucleotide sequence from position 29715472 to 29719566 of NCBI accession No. NC-000080.7. The nucleotide sequence of human IL17RB on fragment A (SEQ ID NO: 5) is identical to the nucleotide sequence from position 53848667 to 53860143 of NCBI accession No. NC-000003.12; the connection of the downstream of the human IL17RB sequence with the mouse is designed to be 5' -aggtgaataagctttgttttttccagacaaaagcaagccgggaggctggctgcctctcttcctggtgctgctggtggctgtgtgg-3' (SEQ ID NO: 6), wherein the sequence "agccg"the last" g "of" is the last nucleotide, sequence, of a human "ggaggThe first "g" of "is the first nucleotide of the mouse sequence.

The targeting vector also comprises a resistance gene used for positive clone screening, namely neomycin phosphotransferase coding sequence Neo, and two site-specific recombination system Frt recombination sites which are arranged in the same direction are arranged on two sides of the resistance gene to form a Neo cassette (Neo cassette). Wherein the connection between the 5 'end of the Neo box and the mouse gene is designed to be 5' -tttctacatagtcttgctgtggtgcacagggtgtggctgaacttcataggGATATCGAATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGG-3' (SEQ ID NO: 7), wherein the sequence "atagg"the last" g "of" is the last nucleotide, sequence "of the mouse"GATAT"G" of "is the first nucleotide of the Neo cassette; the connection between the 3 'end of the Neo box and the mouse gene is designed to be 5' -TCTCTAGAAAGTATAGGAACTTCATCAGTCAGGTACATAATGGTGGATCCggtagaagaaccctaccacctgcagggagaaaatggtacaaatcacagtt-3' (SEQ ID NO: 8), wherein the sequence "GATCC"the last" C "of a" is the last nucleotide, sequence of the Neo cassette "ggtag"the first" g "of" is the first nucleotide of the mouse. In addition, a coding gene with a negative selection marker (diphtheria toxin a subunit coding gene (DTA)) was constructed downstream of the 3' homology arm of the targeting vector. The mRNA sequence of the humanized mouse IL17RB after being transformed is shown as SEQ ID NO: 9, the expressed protein sequence is shown as SEQ ID NO: shown at 10.

Given that human IL17RB has multiple isoforms or transcripts, the methods described herein can be applied to other isoforms or transcripts.

The construction of the targeting vector can be carried out by adopting a conventional method, such as enzyme digestion connection and the like. And carrying out preliminary verification on the constructed targeting vector by enzyme digestion, and then sending the targeting vector to a sequencing company for sequencing verification. The method comprises the steps of performing electroporation transfection on a targeting vector which is verified to be correct by sequencing into embryonic stem cells of a C57BL/6 mouse, screening the obtained cells by using a positive clone screening marker gene, detecting and confirming the integration condition of an exogenous gene by using PCR and Southern Blot technology, screening correct positive clone cells, detecting clones which are verified to be positive by PCR by using Southern Blot (cell DNA is digested by NdeI or BamHI or AseI respectively and hybridized by using 3 probes, the lengths of the probes and target fragments are shown in Table 1), and detecting the result as shown in figure 4, wherein the detection result shows that 12 clones which are verified to be positive by PCR are detected, and the detection result shows that the clones are all positive by sequencing and have no random insertion, and the specific numbers of the clones are 1-C07, 1-C10, 1-G08, 2-B10, 2-D04, 2-D09, 2-F02, 2-F07 and 2-F07, 2-H06, 3-A08, 3-D07 and 3-E04.

Table 1: specific probes and target fragment lengths

Wherein the PCR assay comprises the following primers:

F1：5’-GGCCTTGCTTGCATATTGTTCCAC-3’（SEQ ID NO：11），

R1：5’-GTCTGGTCTTCGATGACCTATTGCC-3’（SEQ ID NO：12）；

F2：5’-GCTCGACTAGAGCTTGCGGA-3’（SEQ ID NO：13），

R2：5’-TAGTTAGGAGCTAAAGCGGTCAGGC-3’（SEQ ID NO：14）；

the Southern Blot detection comprises the following probe primers:

5 'Probe (5' Probe):

5’Probe-F：5’-TGAACCCCTGGACATGAAGGTT-3’（SEQ ID NO：15），

5’Probe-R：5’-AGGCCAGTGATGACAGGCTTA-3’（SEQ ID NO：16）；

3 'Probe (3' Probe):

3’Probe-F：5’-GCTACATGACACGTTCATCAGGATG-3’（SEQ ID NO：17），

3’Probe-R：5’-TGTAAATCCTGGCTTGGTTGCTG-3’（SEQ ID NO：18）；

neo Probe (Neo Probe):

Neo Probe-F：5’-GGATCGGCCATTGAACAAGAT-3’（SEQ ID NO：19），

Neo Probe-R：5’-CAGAAGAACTCGTCAAGAAGGC-3’（SEQ ID NO：20）。

the selected correctly positive cloned cells (black mice) are introduced into the separated blastocysts (white mice) according to the known technology in the field, the obtained chimeric blastocysts are transferred into a culture solution for short-term culture and then transplanted into the oviduct of a recipient mother mouse (white mouse), and F0 generation chimeric mice (black and white alternate) can be produced. The F1 generation mice are obtained by backcrossing the F0 generation chimeric mice and the wild mice, and the F1 generation heterozygous mice are mutually mated to obtain the F2 generation homozygous son mice. Alternatively, positive mice may be mated with Flp tool mice to remove the positive clone selection marker gene (see FIG. 5 for a schematic diagram of the process), and then mated with each other to obtain humanized homozygote mice containing the IL17RB gene. The somatic genotypes of the progeny mice were identified by PCR (primers shown in Table 2), and the results of identification of exemplary F1 generation mice (with the Neo marker gene removed) are shown in FIG. 6, in which all 5 mice numbered F1-01, F1-02, F1-03, F1-04, and F1-05 were positive heterozygous mice.

Table 2: primer name and specific sequence

This indicates that using this method, it is possible to construct a humanized mouse of IL17RB gene that can be stably passaged without random insertion.

The expression of humanized IL17RB mRNA in positive mice can be confirmed by conventional detection methods, such as RT-PCR. Specifically, 1 mouse of a 6-week-old female C57BL/6 wild-type mouse and 1 mouse of the IL17RB gene humanized homozygote prepared in this example were each taken, and after cervical euthanasia was removed, thymus tissue was taken, and ground to prepare a cell suspension, cell RNA was extracted according to the instructions of TRIzol kit, and after reverse transcription into cDNA, RT-PCR detection was performed, and the detection results are shown in fig. 7. As can be seen from FIG. 7, murine IL17RBmRNA was detected in the thymus of C57BL/6 wild-type mice (FIG. 7A), and humanized IL17RBmRNA was not detected (FIG. 7B); only humanized IL17RBmRNA was detected in thymus tissue of a humanized homozygote mouse for IL17RB gene (FIG. 7B), and no murine IL17RBmRNA was detected (FIG. 7A).

The RT-PCR primer sequence comprises:

mIL17RB-F：5’-TCGTCAAGACAAGTGTGGCA-3’（SEQ ID NO：28）

mIL17RB-R：5’-CGACAGACGGTGTGATGGAA-3’（SEQ ID NO：29）

hIL17RB-F：5’-ACACAGTCTATTTCATTGGGGC-3’（SEQ ID NO：30）

hIL17RB-R：5’-CAGGCACTGTCACAAAGGGT-3’（SEQ ID NO：31）

GAPDH-F：5’-TCACCATCTTCCAGGAGCGAGA-3’（SEQ ID NO：32）

GAPDH-R：5’-GAAGGCCATGCCAGTGAGCTT-3’（SEQ ID NO：33）

example 2 preparation of double-humanized or multiple double-humanized mice

A double-humanized or multi-humanized mouse model can be prepared by using the method or the prepared IL17RB mouse. For example, in example 1, the embryonic stem cells used for blastocyst microinjection may be selected from mice containing other gene modifications such as PD-1, PD-L1, IL17A, IL17F, IL17RA, and IL17RC, or may be used in a two-gene or multi-gene modified mouse model of IL17RB and other gene modifications based on humanized IL17RB mice by using isolated mouse ES embryonic stem cells and gene recombination targeting techniques. The homozygote or heterozygote of the IL17RB mouse obtained by the method can also be mated with homozygote or heterozygote of other gene modification, the offspring of the homozygote or heterozygote is screened, the homozygote or heterozygote of humanized IL17RB and double-gene or multi-gene modified heterozygote of other gene modification can be obtained with a certain probability according to Mendel genetic rule, then the heterozygote is mated with each other to obtain double-gene or multi-gene modified homozygote, and the in vivo efficacy verification of targeted human IL17RB and other gene regulators can be carried out by using the double-gene or multi-gene modified mouse.

The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.

It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.

In addition, any combination of the various embodiments of the present invention is also possible, and the same should be considered as the disclosure of the present invention as long as it does not depart from the spirit of the present invention.

Sequence listing

<110> Baiosai Diagram (Beijing) pharmaceutical science and technology Co., Ltd

Construction method and application of <120> IL17RB gene humanized non-human animal

<130> 1

<160> 33

<170> SIPOSequenceListing 1.0

<210> 1

<211> 499

<212> PRT

<213> Mouse (Mouse)

<400> 1

Met Leu Leu Val Leu Leu Ile Leu Ala Ala Ser Cys Arg Ser Ala Leu

1 5 10 15

Pro Arg Glu Pro Thr Ile Gln Cys Gly Ser Glu Thr Gly Pro Ser Pro

20 25 30

Glu Trp Met Val Gln His Thr Leu Thr Pro Gly Asp Leu Arg Asp Leu

35 40 45

Gln Val Glu Leu Val Lys Thr Ser Val Ala Ala Glu Glu Phe Ser Ile

50 55 60

Leu Met Asn Ile Ser Trp Ile Leu Arg Ala Asp Ala Ser Ile Arg Leu

65 70 75 80

Leu Lys Ala Thr Lys Ile Cys Val Ser Gly Lys Asn Asn Met Asn Ser

85 90 95

Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Ser Gln Thr

100 105 110

Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Val Gly Phe Pro Val

115 120 125

Glu Leu Ser Thr Leu Tyr Leu Ile Ser Ala His Asn Ile Pro Asn Ala

130 135 140

Asn Met Asn Glu Asp Ser Pro Ser Leu Ser Val Asn Phe Thr Ser Pro

145 150 155 160

Gly Cys Leu Asn His Val Met Lys Tyr Lys Lys Gln Cys Thr Glu Ala

165 170 175

Gly Ser Leu Trp Asp Pro Asp Ile Thr Ala Cys Lys Lys Asn Glu Lys

180 185 190

Met Val Glu Val Asn Phe Thr Thr Asn Pro Leu Gly Asn Arg Tyr Thr

195 200 205

Ile Leu Ile Gln Arg Asp Thr Thr Leu Gly Phe Ser Arg Val Leu Glu

210 215 220

Asn Lys Leu Met Arg Thr Ser Val Ala Ile Pro Val Thr Glu Glu Ser

225 230 235 240

Glu Gly Ala Val Val Gln Leu Thr Pro Tyr Leu His Thr Cys Gly Asn

245 250 255

Asp Cys Ile Arg Arg Glu Gly Thr Val Val Leu Cys Ser Glu Thr Ser

260 265 270

Ala Pro Ile Pro Pro Asp Asp Asn Arg Arg Met Leu Gly Gly Trp Leu

275 280 285

Pro Leu Phe Leu Val Leu Leu Val Ala Val Trp Val Leu Ala Ala Gly

290 295 300

Ile Tyr Leu Thr Trp Arg Gln Gly Arg Ser Thr Lys Thr Ser Phe Pro

305 310 315 320

Ile Ser Thr Met Leu Leu Pro Leu Ile Lys Val Leu Val Val Tyr Pro

325 330 335

Ser Glu Ile Cys Phe His His Thr Val Cys Arg Phe Thr Asp Phe Leu

340 345 350

Gln Asn Tyr Cys Arg Ser Glu Val Ile Leu Glu Lys Trp Gln Lys Lys

355 360 365

Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Thr Thr Gln Lys Gln

370 375 380

Ala Ala Asp Lys Val Val Phe Leu Leu Pro Ser Asp Val Pro Thr Leu

385 390 395 400

Cys Asp Ser Ala Cys Gly His Asn Glu Gly Ser Ala Arg Glu Asn Ser

405 410 415

Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys Ser Asp Phe Ser

420 425 430

Ser Gln Thr His Leu His Lys Tyr Leu Val Val Tyr Leu Gly Gly Ala

435 440 445

Asp Leu Lys Gly Asp Tyr Asn Ala Leu Ser Val Cys Pro Gln Tyr His

450 455 460

Leu Met Lys Asp Ala Thr Ala Phe His Thr Glu Leu Leu Lys Ala Thr

465 470 475 480

Gln Ser Met Ser Val Lys Lys Arg Ser Gln Ala Cys His Asp Ser Cys

485 490 495

Ser Pro Leu

<210> 2

<211> 502

<212> PRT

<213> human (human)

<400> 2

Met Ser Leu Val Leu Leu Ser Leu Ala Ala Leu Cys Arg Ser Ala Val

1 5 10 15

Pro Arg Glu Pro Thr Val Gln Cys Gly Ser Glu Thr Gly Pro Ser Pro

20 25 30

Glu Trp Met Leu Gln His Asp Leu Ile Pro Gly Asp Leu Arg Asp Leu

35 40 45

Arg Val Glu Pro Val Thr Thr Ser Val Ala Thr Gly Asp Tyr Ser Ile

50 55 60

Leu Met Asn Val Ser Trp Val Leu Arg Ala Asp Ala Ser Ile Arg Leu

65 70 75 80

Leu Lys Ala Thr Lys Ile Cys Val Thr Gly Lys Ser Asn Phe Gln Ser

85 90 95

Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Thr Gln Thr

100 105 110

Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Ile Gly Phe Pro Val

115 120 125

Glu Leu Asn Thr Val Tyr Phe Ile Gly Ala His Asn Ile Pro Asn Ala

130 135 140

Asn Met Asn Glu Asp Gly Pro Ser Met Ser Val Asn Phe Thr Ser Pro

145 150 155 160

Gly Cys Leu Asp His Ile Met Lys Tyr Lys Lys Lys Cys Val Lys Ala

165 170 175

Gly Ser Leu Trp Asp Pro Asn Ile Thr Ala Cys Lys Lys Asn Glu Glu

180 185 190

Thr Val Glu Val Asn Phe Thr Thr Thr Pro Leu Gly Asn Arg Tyr Met

195 200 205

Ala Leu Ile Gln His Ser Thr Ile Ile Gly Phe Ser Gln Val Phe Glu

210 215 220

Pro His Gln Lys Lys Gln Thr Arg Ala Ser Val Val Ile Pro Val Thr

225 230 235 240

Gly Asp Ser Glu Gly Ala Thr Val Gln Leu Thr Pro Tyr Phe Pro Thr

245 250 255

Cys Gly Ser Asp Cys Ile Arg His Lys Gly Thr Val Val Leu Cys Pro

260 265 270

Gln Thr Gly Val Pro Phe Pro Leu Asp Asn Asn Lys Ser Lys Pro Gly

275 280 285

Gly Trp Leu Pro Leu Leu Leu Leu Ser Leu Leu Val Ala Thr Trp Val

290 295 300

Leu Val Ala Gly Ile Tyr Leu Met Trp Arg His Glu Arg Ile Lys Lys

305 310 315 320

Thr Ser Phe Ser Thr Thr Thr Leu Leu Pro Pro Ile Lys Val Leu Val

325 330 335

Val Tyr Pro Ser Glu Ile Cys Phe His His Thr Ile Cys Tyr Phe Thr

340 345 350

Glu Phe Leu Gln Asn His Cys Arg Ser Glu Val Ile Leu Glu Lys Trp

355 360 365

Gln Lys Lys Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Ala Thr

370 375 380

Gln Lys Lys Ala Ala Asp Lys Val Val Phe Leu Leu Ser Asn Asp Val

385 390 395 400

Asn Ser Val Cys Asp Gly Thr Cys Gly Lys Ser Glu Gly Ser Pro Ser

405 410 415

Glu Asn Ser Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys Ser

420 425 430

Asp Leu Arg Ser Gln Ile His Leu His Lys Tyr Val Val Val Tyr Phe

435 440 445

Arg Glu Ile Asp Thr Lys Asp Asp Tyr Asn Ala Leu Ser Val Cys Pro

450 455 460

Lys Tyr His Leu Met Lys Asp Ala Thr Ala Phe Cys Ala Glu Leu Leu

465 470 475 480

His Val Lys Gln Gln Val Ser Ala Gly Lys Arg Ser Gln Ala Cys His

485 490 495

Asp Gly Cys Cys Ser Leu

500

<210> 3

<211> 3924

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 3

tggcatcctt gcctgagtat tctcccatat cttccacccc tttctacccc cttcacccaa 60

ctcttcctct ctcctttgcc accagattct tctccgggat aagaaaccca actagctgcc 120

ctgagccatt tctcaaaaca agccaatcaa gtacccaatt ccttatgttt gtcccacctc 180

cccttgccaa ggtcaggaga ggtcgctcca gtttctgtgt gcatgtgaca tcaagaactt 240

tcctgcccgc ctttctgtct caggggccaa gaaatggctg acttgtccct ggacctgacc 300

tctctatccc tgctgtccca aagccccttg ccttttgcct tgagctgact acagcaggct 360

gtgttctgcc agagcagccc agggactggc actcagctac tcaccgagta aacacgtgtt 420

ggcaatcggc tgtgacttgc tcagctgaga gggagtgctc tctacttgct ctgcacagcc 480

ccatgggctg tttttcaaaa ctggaaactg attgttatct aaacatctgc ctggctcctc 540

agccccatag ggcaaagttc tcagatagaa gctggaaaac aaggccgtct ccattttgtc 600

ttcccaccag ggcaggtact ctggccttgc atgttcctgt cacagtgctc agctccatgc 660

caagagcatg cacctttgca ccctggtagc aggcaagggt ttaccggtca gaaaggctgc 720

tatgaaagct tattgttccc aggaaccact gagcctgaac ggctcgctga ggttgagtgg 780

gagcccagga tggcccagtt ccaggcgagg gtggggctac aacctccctt ctgtcaatct 840

ccttggtcag gcaccagaac aagtttctca ggaaactatt ccttgcaatc caacagaggc 900

tagggacgga gccttctcca ggtgaatcaa aaccagaatc ttcacctgaa gtctgtctca 960

ctgatgaatt tagtctgtat cccagtcggg cttcagcaaa tacagccact tgactccacc 1020

caacctctta gcagggagaa gcaggacttg tgcctgaagc tctctccaat tccactgtct 1080

acgtgtctgg tgagcccagc tctgctaacg atataggaag ggctgaagca gcagaattcc 1140

aggctctgta gccctttctc taaccccaaa tgatactggg ctatccccct ctcaagccat 1200

ttcatctcaa aaggatggtc cctggcccac cttcccaaaa ttaaggtccg agaggtggtg 1260

gagagtcggg cagatctcac tcaggcagaa gcagcactgc caaatgtcag aaccttagct 1320

cggaacccac agtgctgaga caccagcttc gggaccccag atgtaaccgc caggcctcat 1380

tctataggag tacacttaac cagaaagcct gagaggccag gggtggagat tcctatcact 1440

gttaccttgt aactgttaag ttcctgtcgc tagttctctc aaaacccaga aggtttcagt 1500

ggcttgagcc cctccgcttc aggtcctcac ccagcctagg acctgaaaag ctagctactc 1560

acccgggaca actccgcacc tgggccagga cgcgaaggac aggagccagg agagccgaga 1620

aggcagtggc cgctgatcct cgcccgctgc tctttaactg gcgtcccggg agtgccgcga 1680

gctgctccgt ctggctccag gcgcgggtgc ggtcgcccca cctggcctgc ggcacacacc 1740

tgtgcgcggg gctcgacacg ccccgcgcct gctggagctt cagtcctccc gggcctgagt 1800

cattcgcacc ccgcctaccc ccgcgagccc cgagggcgac aaggcggcca ctttactgtc 1860

ttgggaccag gccagcgccg gcttgggcag ggcggtactg tgggaggcgg agcccggaga 1920

actgcggcgg gcgcctggat aagaggaccc tggacctctg gccccagctc cgcgtggtgg 1980

tgggcggtgg ccagtggccg ggccatgttg ctagtgttgc tgatcttggc tgcatcgtgc 2040

aggagcgccc tgcctcgaga gccggtaagc atccccctcc attgtgggca ccctttcggt 2100

tcccatccgt ttagctgaac cctgacaagc gacaagcgcc tgaaaacctg ccagctcaac 2160

tgtcaaggaa ttgtccatga accatcctta gaaaggggcc agtttgcacc cctgagctaa 2220

ccgcgatggg tcttgaactc acaccaccca tctattgcca tcctggaagg tatcagttgt 2280

cagactgctt cccaggggaa tgaggtttag aactgtcaca gatgccacct gggcatttga 2340

gtcgtagtat tctcctcaaa aagaaaaagg gtggtactca actcacacag gtatgccttg 2400

tcctgggtta atgatgacaa acaagacagt actgcttaca tctgtgctgc ccacctcttg 2460

ggtcaacaga cagcctgcat cagtttgctt gcttgctttt cctttctgtc tagggccatg 2520

ttaactcctg aaggcagctt tcctttcttc tccagtcccc atgaatgaaa gaatctttct 2580

aggagggaaa agcgcatcct caacaaggca ttcagatgca agccctgctc tcttcacaca 2640

ttggaaggca tccttggtga ctgtggaaag tcacagctta tttatggtgt cctgaagccc 2700

ttgccgtctc tgtgcaagag aaaaaaactg tcctgggggc agctgtgaag aacattgaat 2760

gaactctgca aaatgtagag ccctcacctg gcttttccta cacaccttgt cttgctccca 2820

ttcaagtaga acttggttcc tagtaggtgg ctcatttgct taataagaga atgtcacaaa 2880

gcaaaggaca gtggatgaca tcatccaaac cccatttgct ccatcaaaac ctctgctttc 2940

tgccttcacc aaggttttgg aaatgagaga gctgagatct taagagtcct ttgggtttgt 3000

cacattgtgt cttgccactg aagattactg acaactaaaa taaatgtttt aggctcaata 3060

tactatttcc aaactagtac tcttcccttt taatggaaac gtcaaagggt ttagtaactg 3120

gcctttcgta gacagtaggg gggttttact tttttgaaag ctgttttaga aagatgaggt 3180

cactgtcccc aacggatttc taagtagctc agctgagttc tggatcattc agaagtatga 3240

tatgagcttg tgtgtgtgtg tgtgtgtgtg tcctgcgggc tgcagtcatt gctccccgct 3300

ttcttctcct ctttgcatag ccaatcttta atttgaagaa attaataaac attacatggt 3360

cctgaaaacc aacagttaag cattagatga tacaagtggc ctcaccgtgg ccctcagtaa 3420

tccgaggcag ggaaagaaag catgcatgag gcctacctgg tcttcaaggg ggtgagcagc 3480

tgccagaaaa ccaggtgtac caatggctaa gccagggccc atcacagcta cagtggggca 3540

gctcaattcc cctcaagttg gaaagtgcaa tcaaactagc tcttttcttt taaaacattt 3600

aaagaattgt atttttaatt tgtgtgtgtg tgtgtgtgtg tgccctcaga aaccacgact 3660

atgatttctg gagctagagt gacaggcaat tgctgtgagt tgtccagtat gggagctgga 3720

gcctaaatgc aggttttctg caagaacaat atgctgtctt aaccactgat tcatctctcc 3780

agctcccggc tcatcttttc gttgaaaact tgtcacttgt atatgcatct aaggaacaat 3840

attggtgtgg tgcctaattt ggtaaagtga ggagtgtggt ttactggctt caacatgaca 3900

tttggtttct ctttcctgca gact 3924

<210> 4

<211> 4095

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 4

ggtagaagaa ccctaccacc tgcagggaga aaatggtaca aatcacagtt gacccaactc 60

ctaaaatgat aagtagaggt cacatctgtg tcacagtaca gaagtttcag cagcttgctt 120

taaacacagt gacctcaaac ctcagcagct gctgagttta tctgaaaaga acagggcttg 180

actatgaagg ctgatttgtt gataaggact taaaaataca tcttttcaag tgcttttaag 240

attcaagcat cagtgtttca ggtattcaaa aggactatca aggacctttt ctcctgtcgg 300

gaacaaagct ctgaccctga tctggctgac agtctggtgg ggagccttta gtagttttag 360

actactgtaa aggcctgcta tctgtcacac agttaacaaa gtccccccct tctcctccag 420

gaaggagcac gaagacgtcc tttcctattt ccaccatgct cctgcccctc attaaggtcc 480

tggtggttta tccttctgag atatgtttcc atcacaccgt ctgtcgcttc actgactttc 540

ttcaaaacta ctgcagaagt gaggtcatcc ttgaaaaatg gcagaaaaag aaaatcgccg 600

agatggggcc ggtacagtgg ctgaccactc agaagcaagc ggcagataaa gtggtcttcc 660

ttcttcccag tgacgtcccg accctttgtg acagtgcctg tggccacaat gagggcagcg 720

ccagggagaa ctctcaggat ctgttccctc ttgcctttaa cctcttttgt agtgatttca 780

gcagccagac gcatctgcac aaatacctgg tggtctatct tgggggagca gacctcaaag 840

gcgactataa tgccctgagt gtctgccccc aatatcatct catgaaggac gccacagctt 900

tccacacaga acttctcaag gctacgcaga gcatgtcagt gaagaaacgc tcacaagcct 960

gccatgatag ctgttcaccc ttgtagtcca cccgggggaa tagagactct gaagccttcc 1020

tactctccct tccagtgaca aatgctgtgt gacgactctg aaatgtgtgg gagaggctgt 1080

gtggaggtag tgctatgtac aaacttgctt taaaactgga gtttgcaaag tcaacctgag 1140

catacacgcc tgaggctagt cattggctgg atttatgaag acaacacagt tacagacaat 1200

aatgagtggg acctacattt gggatatacc caaagctggg taatgattat cactgagaac 1260

cacgcactct ggccatgagg taatacggca cttccctgtc aggctgtctg tcaggttggg 1320

tctgtcttgc actgcccatg ctctatgctg cacgtagacc gttttgtaac attttaatct 1380

gttaatgaat aatccgtttg ggaggctctc actaatgtgt agcttcctaa gagaagaagc 1440

ctattacaca cacaagcaga cactctgcct gaccagatga tccagtttat gtgtaaccac 1500

tgtactgttt gctgttggga cagtgctttc ccttgccaaa cttttggaca ggtaaccttt 1560

accttttatc ttagaagggc taggaactga acccagggta ttatgcacac tagacaaatg 1620

ctctgacact gaattacacc tcagtctccc acgggtgact ctctaagtga atatgcaagc 1680

atatcaccag cagggcggtg gtggcacacg cctttaatcc cagcactcgg gaggcagagg 1740

caggcggatt tctgagttca aggtcagctt ggtctacaga gtgagttcca ggacagccag 1800

ggctacacag agaaaccctg tcttggaaaa accaaaaaaa ctaaccaatc aaccaaagcc 1860

ccacatcacc agctggatgt ggtggcacgt ggcacatacc tttaatccca gcactcaagt 1920

ggaagaggca ggaggacctc tgggtgtgtg aggccagcca gagacagagt gaggctctgt 1980

cccaaacaaa cacaagttgc tacctataaa tccagtgtct acttttgtcc agttacctgt 2040

ccactattga agttcgcaga gttcttggtt attacataac atttcctatt caagtcaaaa 2100

ctaattcttc aagtgagatc aactctcttt aagtaatata tctttttcta taactaattg 2160

cgtaaataaa aacccaccaa gaactggaga ggtggctccg aggcttagag cgctggctgc 2220

tcttccagag gacttggttc ggtttccagc aaccacatag ctgtttatag ccaccttaac 2280

tccagtgtca aagggatctg ataaccctct ctggcttccc aggccactct ccatgcattt 2340

tacaaagaca ttttatatac agcaggactt tgcttgcatg tatgtctgtg taccacatgt 2400

gcttggtgcc tgaggtcagg cgagggtgcc ggatgccctg gaactggaat taggaacaga 2460

tgtgagccac catgtggact ctgggaatcc aatcccagtc tcctgcaaga acaaatgctc 2520

ttaactgatt cgctatctag ctatacccca atgtaaataa atcttaattt aaatctaaaa 2580

taaaccccca accagaacaa gcaggaacag tatacagcct tgctaggtct tgaatcttct 2640

agctccttac gttctcaaag cagctttttc ttaatgtaga aactacagca atgtatatta 2700

tcataagtat ttgtctagta tggcttcata acgcacgatc aatctatttt gaaatgggac 2760

cctgtttcag gtagttgact gctttgatat ctgtacctga aggtctggca tgttggacac 2820

ccctttaatc ctagggctcc gaggcagaag caggcaaatc tcttgagttc gaggccagcc 2880

tggtctacac agtaagttcc aggacagcca gggctacata actgagaaac cttgtttaaa 2940

aaacaaaaaa caaaacaaaa gcaagtttgt aattgatccg gtaagtagca aacactttta 3000

aaaactatgt atttttaatt atgtcttagg ggtgtgtgtg tgtatctgca atgggtatgt 3060

gcatgtgagt atccactcac aagagtatct atccactcag aagtatgact cacaagaggc 3120

caaaggcctc agatgcctta gggctggagc tacagatggt tgggagcggc ctgacctgcg 3180

ctgggacctg aaccccagat cttccagaag agcagcgagt ggccttcctc actgagctgc 3240

ctctccagtt ccctggggca cacattttaa gttgcagtgc actggaagga agcaaacaga 3300

gccgtgggtt ctggggaaag actctgtttc aaaaaaaaaa aaggtcatgt tcgagcattt 3360

gtacatcatg tacaaggtcc tggtttcaat ccacagcaat acaaaaagtg tgctaaagag 3420

ccaatgtaaa agggattcat tcactctagc acaagtctta caaataaaat aaaaaccctg 3480

cagccaactt catcagcaaa tactctgata aggtggaggc agtgcaggcg tggcacacga 3540

gcgtcacatc cagtgtatga tgtcagaggc agtgcaggcg tggcaaggct cggctatttg 3600

ggaagacagt tgccagaagc ttgtaaaagt gctgctaaca gatggatata gcttgtgcca 3660

aaacttggac cacaaaccaa cttcctccac atcaacacct accactgtaa gtgaccttca 3720

tgtgcggaat ggtcacaaca ggcgcactgt gcttcgggga gcgcagggat gagtgtcaac 3780

tgtccaatca gcccagaaac ataaaagcat atcctataca tttgatccaa aacataaaaa 3840

gcaggtaatt ttcaaatgag gaagtacatc tccaaatagt atgccccgct tgctcgaagc 3900

tgctttagct ggttactctt acagcgccag cagggctgtg cacccgagac tgctacagtc 3960

catggtgatc ccgcggctca tctgacccac tgttacctgc ctcccagtcc tccccaggac 4020

aagcctggtg acagacacgg taggagcaga tgcctaacag ccagctaaac aattctgctc 4080

tacctaccct gcctg 4095

<210> 5

<211> 11477

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 5

gttcaatgtg gctctgaaac tggtaggtgc attagagaat gggtatttgg ggctttacat 60

tgaaagcaca gttggacttt taggaagcct aatataggca ataggtcatc gaagaccaga 120

cacagggtga cccattgctt tattggctga tgcagatgaa gtctctgtct gctcgaagca 180

gaactctggg gctctgtggg aatgaggccg tgtttcagac aggctagcct cttggccagt 240

caagatggga cttgccatac aaggtggaaa gtgatgcctg ccactctgca gagggagatc 300

aaggccgtgg aaggaaggtc acttagagtt gggaccgaga agcaaatgtt tcataggaga 360

gcgggtgttt gagatggtgg catttgaaga atgggtaggc ttctgcccaa aaaatgtggg 420

taggaagagt gagctggagg agagatggca ccagcaaagg ttaggaggtg ggaaagtggg 480

ggctgtgtgg gccagctggc tggaatccag ggccaaagcc tgaggaaggc aggcctgact 540

ctaataaaca tgtcaaatac actaaatata tacatgtgta catacacagg tacctggagt 600

ggtcccacgt gctctgtagg tgaaagccag gaggttgaga gtacttctgt tagatcaaaa 660

ttatctgggc tataaatcag ccagcgctaa gaaacatttg gccttagcag gaagaactga 720

ggaattgggt caggcgtggt ggcttatacc tataatccaa gcactttggg aggctgaggt 780

gggaggatca tttgaggcca ggagtttgag atcatcttag gcaacagagt gagaccccat 840

ctctacaaaa aacatttttt taattaaaaa aaaaagaagt gaggaattgt gaatggggga 900

aggtttggtg tgagtcactg agaggagatg gcatggcatc agactgggct gggaaagaca 960

gtgtcatgga agtcttgctt tttcccaggg ccatctccag agtggatgct acaacatgat 1020

ctaatccccg gagacttgag ggacctccga gtagaacctg ttacaactag tgttgcaaca 1080

ggggactatt caattttgat gaatgtaagc tgggtactcc gggcagatgg taagtttgca 1140

tccatcagag ataaggccca aagtgtctac taaatcagaa atgtgcagac tatatgaacc 1200

attaattccc cttctacgca taaccaacag aaatacatgc atacacgcac caaaagccac 1260

atactagggt gatcgcagta gcactactta caacaggcaa cattagaaag cactcaaatg 1320

cccaacagta gaaaggaatc accagataaa ttccgtcaca gcaacaagaa tgaatgatct 1380

gtaactacgt acaacaatat ggatgaatgt cacaaacata aggcagattc aaaagagttt 1440

gtacatttat atctgtgtgc atgcctgcag gcatacatgc catatgatcc catttacaga 1500

aagtgccaag caaacaaaac caatctagtg tttagaagtc aggatagtag ccaggagcgg 1560

tggctaacgc ctgtaatccc agcactttgg gaggccgagg tgggtggatc acttgaggcc 1620

aggagttcga gaccagcctg gccaacatgg caaaacccca tctctactaa gaatacaaaa 1680

attagccaga tgtggtgttg cacacctgta atcccagcta ctcgggaggc tgaggcacga 1740

gaatcgcttg aacccaggag gcggagcttg cagtgagctg tgatcgcacc actgcactcc 1800

agcagcctgg gcaacagagt gaaactccgt ctcaaaaaaa aaaaaaaaag caaaagacca 1860

ggcgtggtgg cgcatgcctg taatcccagc actttgggag gccaaggcgg gtagattact 1920

tgaggtcagg agttcaagac cagcctggcc aacatggtga aactccatct ctcctaaaaa 1980

tacaaaaaat tagccaggca tggtggcaca tgcctgtaat cccagctact tgggaggctg 2040

aggcaggaga ataacttgaa cccaggaggt ggaggttgca gtgagttgag actgtgccat 2100

tgcactcctg cctgggtgac agagagactg tctcaaaata aaataaaata aaataaaata 2160

aaagtcaggg tagtggttcc tgctggggta ggaataactg taaggaagta tgaggagcac 2220

acctgaggga gtttcttaac ctgcatactg gttgcatgag tgtcccgatg catcaagtgg 2280

tacacttatg tgtgtacttt tctgtgtatg tacttcatgg aagaagataa ggtaaggcga 2340

gagatgattt tccccacccc acttcagttt agggaaagca ctggcttaga tagattactt 2400

ttccacttcc cagatgacgt cacgaagctt ttggcatttc cccaagattg tgctgcaagg 2460

caccatatga gttctttcag tgagctactc ctgggatcct aatgcccatc cttttggttt 2520

ccatctgcta aattcagatc ggaaaaaagt ctacctggtc aagaatccat gagtgccagg 2580

cacagagaga ggagtcacct acagtctcca cccaggagga ttcagagggg taggggaggc 2640

agacacaggc acaatgtcag gggagtccca gaagggagct gtgcttcatc tgagtgggat 2700

agggcgagag gagctggaaa gggtctctgg tgaggttgct ttaggtgaga tgtggccata 2760

agggtttggg cccttacctg gcacagagtg agctctttgt cagctgtggt tatgggctgt 2820

ggtgcatgag tgagttgggc tttaaaagag tgaaacttga agaggtagat aatgggagga 2880

aaggaccttc agggagaaga atcagcatgg ataaaggtgc aatcggaaca ggtgtggttt 2940

ggtgatgaca gtcttggagg gtctttgtgg gtctccctga ggccagcctc ttcctcttaa 3000

aagagaccca gaatagtgca gagctatagc cacctttgca ggcatcctat gaaattcaag 3060

ctgacctatg aggaggaggg agcttgggct ttggaatctg aattcgtatc tgctacttgc 3120

tgatgagttt tctaagttta agcagagctc cctgaaactt cctaagcctc acgaacccca 3180

tctgtaaact ggagacagtg gtgcctacct ttcagtacta ttgtgaatat gaaccgagac 3240

ataaaataaa gcatgctagt aaagcatcta gcatcaagtc agccacacag caagtgctaa 3300

ataaaccaat gtcctcttgc ctatctcggc agccagcatc cgcttgttga aggccaccaa 3360

gatttgtgtg acgggcaaaa gcaacttcca gtcctacagc tgtgtgaggt gcaattacac 3420

agaggccttc cagactcaga ccagaccctc tggtggtaaa gtaagcactt ttttgttttt 3480

tgttttgttt tttgagatag catcttgttc tgtcacccag gctggagtgc agtggtgcga 3540

tcatggctca ctgcgacctc aatcttctgg gctcaagcga tcgttctact tcagcctccc 3600

aagcagctgg gactacaggc atgagccacc agacctggct aatttttgta gtttttgtag 3660

aggggggttt caccgtgttg ctggtcttga attccagtgc tcaagcgatc tgcctgcctc 3720

agcttcccaa agtgctggga ttacaggtat gagccactgt atccgggcat agacactttt 3780

atgtatttgg ctaattgttg ctgaaagcta tgccctttgt ttggggagca tggatgatgt 3840

gctgctcaca cgggctggta aatagctatg actcagagct tagagcaaga tcccttggtt 3900

caaatcccat tttcggctac ttctctgttt tgtgcctttt gtaagtcagc atctctgggc 3960

ctcagttttt ccctaccagc caatggaaga gaattggact taaattatat cctggcttta 4020

aaactttata cttctctgat tctgtaaatt gtttagtgcc cattccctaa gtagacattg 4080

gttggagacc taagttttca cagagtgagt aatgaaatac aaactaaaag ggcaacacac 4140

taaggtatac tgtttctgta ctgcagtgtt ttgggaattg agagttcctt gctttgcctt 4200

tcagtggaca ttttcctaca tcggcttccc tgtagagctg aacacagtct atttcattgg 4260

ggcccataat attcctaatg caaatatgaa tgaagatggc ccttccatgt ctgtgaattt 4320

cacctcacca ggtaaacttc ctcatttgtt tattattctt tgtcttgctg ggatgcctgc 4380

tttgcgatat gcacagagag agcccaggga accctggata aggcttttgg ccttgctaaa 4440

tctcagttcc cttatctaaa gcatggacac agtagtaacc atactttacc cacagagcag 4500

agagaataaa gtcaggtaaa atgtaggaaa aagtctgttc ctgtatgcca ggcactgtgc 4560

tgaatacttg atatgcatca tctcacttaa gcatctcagc aaccccaagg ttgggatagc 4620

tgcattttac agatgaagaa actgagaggt taagtcactt tccctgggtt atacacacat 4680

aaaagtgaag ctgacattca cactttggtc cttctagagc aatgcacctg agccactctt 4740

tatatcactg atgcaaaatg tttgttcgtt cctatctcag ctttctagag tgggctgcat 4800

atggctgggc ctctgagaat ctacagactc cagttggctt gtccccaagc tgtccatgag 4860

aggcagggtg gtcctgagtt ggatgctggg cccttgcccc agctttgtga cacaggacca 4920

gttctctggt accacagctg caatgtcaca cacagggctg tgatgaggat gagacaggat 4980

ggtgtgtgtg aagggtctat ctgagccgag tcacccatcc cataccacca tcctgtcatc 5040

tgtcacaggc aaggcatcaa agccaaacgg taatttccaa ttcactgctg gtcttggaga 5100

ttgtggtcca gggtgttttt ggtgctgcac catttactac acgtggtttc caactttctt 5160

gatgagagca aacctcattt tgttttcaaa taagcttttt tattttggaa ttcttttatt 5220

ttattattta tttatttatt tattttttag acggggtttt gctcttgttg ccctggctgg 5280

agtgcagtgg caccatctca gctcactgca acctccgcct cttggattta agtgattctc 5340

ctgcctcagc ctcccaagaa gctaggatta cagtcatgag ccaccacacc cagctaattt 5400

ttgtattttt agtagagacg gggtttcact atgatggcta ggctagtctc aaactcctaa 5460

cctcgggtga tctgcctacc ttggcctccc aaagtgctgg gattacagga gtgagccacc 5520

gtacccagcc ttattttgga ataattttag atttacagaa aagttgcaaa gatagtacag 5580

tttccatata cctctcaccc agcttctcct attaacgtct tgtattacca tgatacattt 5640

gtcaaaacta agaaaccaac attagtacgt gtctgttaac taaactccag actttatttg 5700

gacttcacct gctttttcat gaatgtcctc tttctgttcc agttgcattt agtccctgtg 5760

tgtctctcct ctggtctgta acagtttctt agtctttgtt tttcagaacg ttgacagtct 5820

tgagttctga ccaggcatcc tgtagaatgt cccccagtgt gggtttgtct gatgtttgtc 5880

tcatgattag acagggaatt cataccacag aggtgccggg cccttcttat cccatcaggg 5940

gtccatggca cccacatgac accaggctgg gggtcaccat caacactaga ttaatgtggg 6000

gactgccaga cttctccatg taaatctact gtttttccca actctcgttt ttggaaacaa 6060

gtcactaatt ctaccccacc ctggggtgag gataggggag tgttaggctt catgtccttg 6120

aaggggcagc atctacagat attaccaaat gtccttttca aatgatggat ggttttcgag 6180

tcctctctta gggatcaaag atactgtttt gataaaggct gtatttaaat tagactctgg 6240

ttatcacgta atgggcagat gttctctgtt tagcagtaaa atgttagagc cccacaaaaa 6300

attagccggg cgtggtggcg ggcgcctgta gtcccagcta ctcaggagcc tgaggcagga 6360

gaatggcgtg aacctgggtg gcagagctag cagtgagctg agattgcgcc actgcactcc 6420

agcctaggcg acagagcaag actccggctc aaaaaaaaaa aaaaaaaaaa aaaaattaga 6480

gccccatttg aatttgccat cttacatctg gaatgttttg gcaatttgtt acaggtgtgg 6540

tatgcgtatg tgtgtgtgca cttggcaaag ggggtggggc agagatacct ttttctaaaa 6600

tgtaaaaact ttcattcaaa tttccaggct gcctagacca cataatgaaa tataaaaaaa 6660

agtgtgtcaa ggccggtaag taaatacggc atttgctttt attatttgaa gaaacttgta 6720

acttgaggca gcatagctct cttcatcttt gcacagaaga actgagccct aggggagagt 6780

tgaatatcca agcacccccg atggtggtgg cagaagcacc tatggctcct gatctccagc 6840

cagtactttg cccactgagt gcagcagcct gtccagaaag gggtagaccc tcagtacatt 6900

tatatagtgg agcaacagtc acaaagaacc acccccatcc acttggttaa caacatttta 6960

gcccaaatgg ctcagcagtg ccaatcaaag gctcttcctg attgatggga gtcctacgag 7020

cccttccacc tgctcagatg ctagcaccac ccacctgtgg ccatggggat cctaagaacc 7080

ttctgtttgg attagcaaac attcgaggtg ggagtgtgag ttcgctaaag gactggccca 7140

caattacgct ctcaatttgt gtcctcaaag aggatcactt ttcacaggct agtgaatttt 7200

accccttgaa ttttgtagta atccccttta ggattattag tccctagtgc ccagtttcca 7260

agggtttgtg taaatttctg agtaatatag tgttggaatg ctaatgaggc tagtggtatt 7320

tggatcagcc cagaactctt aggcaccctt cactgcacaa ggcatccctg gtaccctttc 7380

agacagccgt ccatgctgtc cttgctagaa ggcagatttg gacgctgagc ttcccaccaa 7440

gggtacagag aacactgcag gtgtgaggag gtcagagggc cttgaagtca gtcctgaacc 7500

tgaactccta aagacagttc tgagccaggg cctcaaatgg tctcctcggt ggagaagata 7560

atttctgctg ttatacattg ttgttcctgg aaatcagtcc agtccttatt tgcaagtcac 7620

atgaatgaaa cgactgactt tttctgccag agcagaccta tcagggtata tcctctaagc 7680

tacgagccat ttccttcttt ctttgcatct agtgaagctg gcagaatggt ctgatggatg 7740

aagctcctgg aacacaaaat attctagtgg ttgtagtcct gattgtgagt tcacttgctc 7800

tataatctta gacatgtttt ccaacctgta gctctttctc cccatcctgg gaagtagaaa 7860

atactgaccc tatcccttaa ctcaaaagag aggttgaaaa cagcagtgag tagcagaacc 7920

aatccgtgcc tcccaccata ctcagcccag ggaagctgtt tttagcaaag cagcgatgta 7980

cggatcccca aactgtcttg ggcagcaagt actttgagac tttggaaaca atgataaaaa 8040

gttcactatg tagcagcgtc cctatctctt ggacattgtt cctgagaact tgggtttgtt 8100

tccataaagc cctgtgggga acttaaatga gggaagagtt agcaagttca tctacatggt 8160

tctctctcaa ctcacaggaa gcctgtggga tccgaacatc actgcttgta agaagaatga 8220

ggagacagta gaagtgaact tcacaaccac tcccctggga aacagataca tggctcttat 8280

ccaacacagc actatcatcg ggttttctca ggtgtttgag gtactttttc tcttcgtccc 8340

cttcacctcg tcctccagct ttccttagtg tgttgaagga aaatggggac agtgttgtcc 8400

aaacgtgctg ggctactttg atgaattcaa cagataaaaa caagtccctg tgggcatcct 8460

gagaggtgtc actgtgaacc tcaaaccata gaaagaagga agtctccgaa gcaggaaatg 8520

agcccttctt tacacatggt ctagtgaaag gagtcctttt gggaagcaaa gctgctttgc 8580

tggaagcctc gaaatctgct cactcctgtg cctcataatt tttggggggc ggaggttgac 8640

acagggtctc actctgtcat ccaggctgga atgcagtggc acaatcacag cttagtgcag 8700

cctccacctc ccgggctcaa gtgatcctcc cacctcagcc tccccagata gctgggatta 8760

caggcatgtg ccaccatgcc gagctaattt tttcatcttt agtagagacg gtttcgccat 8820

gttgcccagg ctggtctcaa aatactgggc tcaagccatc tgcctgcctt ggcctcccaa 8880

agtgttggga ttacaggggt gagccagtgc acctggcacc tcataattct tgactctctc 8940

tctcttaagc cacaccagaa gaaacaaacg cgagcttcag tggtgattcc agtgactggg 9000

gatagtgaag gtgctacggt gcaggtaaag ttcagtgagc tgctctgggg agggaaggga 9060

catagaagac tgttccatca ttcattgctt ttaaggatga gttctctctt gtcaaatgca 9120

cttctgccag cagacaccag ttaagtggcg ttcatggggg ctctttcgct gcagcctcca 9180

ccgtgctgag gtcaggaggc cgacgtggca gttgtggtcc cttttgcttg tattaatggc 9240

tgctgacctt ccaaagcact ttttattttc attttctgtc acagacactc agggatagca 9300

gtaccatttt acttccgcaa gcctttaact gcaagatgaa gctgcaaagg gtttgaaatg 9360

ggaaggtttg agttccaggc agcgtatgaa ctctggagag gggctgccag tcctctctgg 9420

gccgcagcgg acccagctgg aacacaggaa gttggagcag taggtgctcc ttcacctctc 9480

agtatgtctc tttcaactct agtttttgag gtggggacac aggaggtcca gtgggacaca 9540

gccactcccc aaagagtaag gagcttccat gcttcattcc ctggcataaa aagtgctcaa 9600

acacaccaga gggggcaggc accagccagg gtatgatggc tactaccctt ttctggagaa 9660

ccatagactt cccttactac agggacttgc atgtcctaaa gcactggctg aaggaagcca 9720

agaggatcac tgctgctcct tttttctaga ggaaatgttt gtctacgtgg taagatatga 9780

cctagccctt ttaggtaagc gaactggtat gttagtaacg tgtacaaagt ttaggttcag 9840

accccgggag tcttgggcac gtgggtctcg ggtcactggt tttgacttta gggctttgtt 9900

acagatgtgt gaccaagggg aaaatgtgca tgacaacact agaggtatgg gcgaagccag 9960

aaagaaggga agttttggct gaagtaggag tcttggtgag attttgctct gatgcatggt 10020

gtgaactttc tgagcctctt gtttttcctc agctgactcc atattttcct acttgtggca 10080

gcgactgcat ccgacataaa ggaacagttg tgctctgccc acaaacaggc gtccctttcc 10140

ctctggataa cagtaagtgc ccagtaactt caaccagatg atcaaagtgg ctcacacaca 10200

gtcactgccc cccactcagt atgtggaagg gttgtgtgta tgtgggcagt gcaaggggtc 10260

gctgcctgtg tacactgaac tggggtgcag agaaagccaa cagtgctgtc ccagagaacc 10320

tagaatctga gtaagaacag gctttatttg taaaaccact cgtgactctt tacaaagcag 10380

gatacacaga agggaaaaaa atacacagtg caaaatggat gttctgagtg ccacaaggat 10440

ctgctgaaaa aagccaaaga tgtaagatgg ctgggtatat atgagaatga atatttcact 10500

atattctgat tcaattacca gtctcagtgg cccaggatga gcttttggtg tggtcacatg 10560

gccaacattt ggataacaaa tgaggaataa tggtaccgcc tcactagtgc ctgagaacag 10620

catgttctgg aaaatgtctc tggagttaga gatgtgttag ctttttcatt acagatggag 10680

aaatacaatg tttacacaac agtccagggg tggggtcaaa agttggaagg tgtcattaga 10740

cgcagccaaa taaagtgaag acaacccagg tgactggcag ccctgacttg tgcgtgggcg 10800

aagccttaca gattcctggg cactctgtgc ctgagcttac ctgatgttct tgtgaggcgg 10860

gtggcactat cctccatgta tgtcagtcta acaagacggc ctgtaaaaat gtcatctata 10920

tgtgctatgt atgtaagcag ttgtacccag aataacatta attccttaaa gaaccaaaaa 10980

aactggacag aaaccctagt tcctactgtg aaaatgccgg tgcatatcag gacaaagaag 11040

ccaaagagat tttaggactg ttcttaactt cctgggtccc atatcccttt tgagaatcta 11100

atgcaagacc tgcacactct agggaaaaag atatgattgg cagactctct aaagagcttc 11160

tgactgatgg ttttaaaggg atctaaatct ctacaaagtg gctgggcgcg gtgacacatg 11220

cctgtaatcc cagctactca ggaggctgag gcagcattgc ttgaacccgg gagacggagg 11280

ctgcagtgaa ccgagattgc gccactgcac tccagcctag gcaacaaagc gagactctgt 11340

ctcaaaacta aaaaataata aaaaataaat aaacctctat aaagtatacc aagtcttagt 11400

ttttaaatta agagataagt gtggatttgt tttccaaagg tgaataagct ttgttttttc 11460

cagacaaaag caagccg 11477

<210> 6

<211> 85

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 6

aggtgaataa gctttgtttt ttccagacaa aagcaagccg ggaggctggc tgcctctctt 60

cctggtgctg ctggtggctg tgtgg 85

<210> 7

<211> 100

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 7

tttctacata gtcttgctgt ggtgcacagg gtgtggctga acttcatagg gatatcgaat 60

tccgaagttc ctattctcta gaaagtatag gaacttcagg 100

<210> 8

<211> 100

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 8

tctctagaaa gtataggaac ttcatcagtc aggtacataa tggtggatcc ggtagaagaa 60

ccctaccacc tgcagggaga aaatggtaca aatcacagtt 100

<210> 9

<211> 2070

<212> DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400> 9

gtgggaggcg gagcccggag aactgcggcg ggcgcctgga taagaggacc ctggacctct 60

ggccccagct ccgcgtggtg gtgggcggtg gccagtggcc gggccatgtt gctagtgttg 120

ctgatcttgg ctgcatcgtg caggagcgcc ctgcctcgag agccgactgt tcaatgtggc 180

tctgaaactg ggccatctcc agagtggatg ctacaacatg atctaatccc cggagacttg 240

agggacctcc gagtagaacc tgttacaact agtgttgcaa caggggacta ttcaattttg 300

atgaatgtaa gctgggtact ccgggcagat gccagcatcc gcttgttgaa ggccaccaag 360

atttgtgtga cgggcaaaag caacttccag tcctacagct gtgtgaggtg caattacaca 420

gaggccttcc agactcagac cagaccctct ggtggtaaat ggacattttc ctacatcggc 480

ttccctgtag agctgaacac agtctatttc attggggccc ataatattcc taatgcaaat 540

atgaatgaag atggcccttc catgtctgtg aatttcacct caccaggctg cctagaccac 600

ataatgaaat ataaaaaaaa gtgtgtcaag gccggaagcc tgtgggatcc gaacatcact 660

gcttgtaaga agaatgagga gacagtagaa gtgaacttca caaccactcc cctgggaaac 720

agatacatgg ctcttatcca acacagcact atcatcgggt tttctcaggt gtttgagcca 780

caccagaaga aacaaacgcg agcttcagtg gtgattccag tgactgggga tagtgaaggt 840

gctacggtgc agctgactcc atattttcct acttgtggca gcgactgcat ccgacataaa 900

ggaacagttg tgctctgccc acaaacaggc gtccctttcc ctctggataa caacaaaagc 960

aagccgggag gctggctgcc tctcttcctg gtgctgctgg tggctgtgtg ggtgctggca 1020

gctgggatct acctaacttg gaggcaagga aggagcacga agacgtcctt tcctatttcc 1080

accatgctcc tgcccctcat taaggtcctg gtggtttatc cttctgagat atgtttccat 1140

cacaccgtct gtcgcttcac tgactttctt caaaactact gcagaagtga ggtcatcctt 1200

gaaaaatggc agaaaaagaa aatcgccgag atggggccgg tacagtggct gaccactcag 1260

aagcaagcgg cagataaagt ggtcttcctt cttcccagtg acgtcccgac cctttgtgac 1320

agtgcctgtg gccacaatga gggcagcgcc agggagaact ctcaggatct gttccctctt 1380

gcctttaacc tcttttgtag tgatttcagc agccagacgc atctgcacaa atacctggtg 1440

gtctatcttg ggggagcaga cctcaaaggc gactataatg ccctgagtgt ctgcccccaa 1500

tatcatctca tgaaggacgc cacagctttc cacacagaac ttctcaaggc tacgcagagc 1560

atgtcagtga agaaacgctc acaagcctgc catgatagct gttcaccctt gtagtccacc 1620

cgggggaata gagactctga agccttccta ctctcccttc cagtgacaaa tgctgtgtga 1680

cgactctgaa atgtgtggga gaggctgtgt ggaggtagtg ctatgtacaa acttgcttta 1740

aaactggagt ttgcaaagtc aacctgagca tacacgcctg aggctagtca ttggctggat 1800

ttatgaagac aacacagtta cagacaataa tgagtgggac ctacatttgg gatataccca 1860

aagctgggta atgattatca ctgagaacca cgcactctgg ccatgaggta atacggcact 1920

tccctgtcag gctgtctgtc aggttgggtc tgtcttgcac tgcccatgct ctatgctgca 1980

cgtagaccgt tttgtaacat tttaatctgt taatgaataa tccgtttggg aggctctcac 2040

taatgtgtag cttcctaaga gaagaagcct 2070

<210> 10

<211> 502

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 10

Met Leu Leu Val Leu Leu Ile Leu Ala Ala Ser Cys Arg Ser Ala Leu

1 5 10 15

Pro Arg Glu Pro Thr Val Gln Cys Gly Ser Glu Thr Gly Pro Ser Pro

20 25 30

Glu Trp Met Leu Gln His Asp Leu Ile Pro Gly Asp Leu Arg Asp Leu

35 40 45

Arg Val Glu Pro Val Thr Thr Ser Val Ala Thr Gly Asp Tyr Ser Ile

50 55 60

Leu Met Asn Val Ser Trp Val Leu Arg Ala Asp Ala Ser Ile Arg Leu

65 70 75 80

Leu Lys Ala Thr Lys Ile Cys Val Thr Gly Lys Ser Asn Phe Gln Ser

85 90 95

Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Thr Gln Thr

100 105 110

Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Ile Gly Phe Pro Val

115 120 125

Glu Leu Asn Thr Val Tyr Phe Ile Gly Ala His Asn Ile Pro Asn Ala

130 135 140

Asn Met Asn Glu Asp Gly Pro Ser Met Ser Val Asn Phe Thr Ser Pro

145 150 155 160

Gly Cys Leu Asp His Ile Met Lys Tyr Lys Lys Lys Cys Val Lys Ala

165 170 175

Gly Ser Leu Trp Asp Pro Asn Ile Thr Ala Cys Lys Lys Asn Glu Glu

180 185 190

Thr Val Glu Val Asn Phe Thr Thr Thr Pro Leu Gly Asn Arg Tyr Met

195 200 205

Ala Leu Ile Gln His Ser Thr Ile Ile Gly Phe Ser Gln Val Phe Glu

210 215 220

Pro His Gln Lys Lys Gln Thr Arg Ala Ser Val Val Ile Pro Val Thr

225 230 235 240

Gly Asp Ser Glu Gly Ala Thr Val Gln Leu Thr Pro Tyr Phe Pro Thr

245 250 255

Cys Gly Ser Asp Cys Ile Arg His Lys Gly Thr Val Val Leu Cys Pro

260 265 270

Gln Thr Gly Val Pro Phe Pro Leu Asp Asn Asn Lys Ser Lys Pro Gly

275 280 285

Gly Trp Leu Pro Leu Phe Leu Val Leu Leu Val Ala Val Trp Val Leu

290 295 300

Ala Ala Gly Ile Tyr Leu Thr Trp Arg Gln Gly Arg Ser Thr Lys Thr

305 310 315 320

Ser Phe Pro Ile Ser Thr Met Leu Leu Pro Leu Ile Lys Val Leu Val

325 330 335

Val Tyr Pro Ser Glu Ile Cys Phe His His Thr Val Cys Arg Phe Thr

340 345 350

Asp Phe Leu Gln Asn Tyr Cys Arg Ser Glu Val Ile Leu Glu Lys Trp

355 360 365

Gln Lys Lys Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Thr Thr

370 375 380

Gln Lys Gln Ala Ala Asp Lys Val Val Phe Leu Leu Pro Ser Asp Val

385 390 395 400

Pro Thr Leu Cys Asp Ser Ala Cys Gly His Asn Glu Gly Ser Ala Arg

405 410 415

Glu Asn Ser Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys Ser

420 425 430

Asp Phe Ser Ser Gln Thr His Leu His Lys Tyr Leu Val Val Tyr Leu

435 440 445

Gly Gly Ala Asp Leu Lys Gly Asp Tyr Asn Ala Leu Ser Val Cys Pro

450 455 460

Gln Tyr His Leu Met Lys Asp Ala Thr Ala Phe His Thr Glu Leu Leu

465 470 475 480

Lys Ala Thr Gln Ser Met Ser Val Lys Lys Arg Ser Gln Ala Cys His

485 490 495

Asp Ser Cys Ser Pro Leu

500

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 11

ggccttgctt gcatattgtt ccac 24

<210> 12

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 12

gtctggtctt cgatgaccta ttgcc 25

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 13

gctcgactag agcttgcgga 20

<210> 14

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 14

tagttaggag ctaaagcggt caggc 25

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 15

tgaacccctg gacatgaagg tt 22

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 16

aggccagtga tgacaggctt a 21

<210> 17

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 17

gctacatgac acgttcatca ggatg 25

<210> 18

<211> 23

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 18

tgtaaatcct ggcttggttg ctg 23

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 19

ggatcggcca ttgaacaaga t 21

<210> 20

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 20

cagaagaact cgtcaagaag gc 22

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 21

ggacagtcac ttgctacaca cgtt 24

<210> 22

<211> 23

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 22

aagtgaccac cacccttacc ttg 23

<210> 23

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 23

gctgaggcag cattgcttga ac 22

<210> 24

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 24

gggagttatt cctatgtcat ggcca 25

<210> 25

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 25

aaatcagcct tcatagtcaa gccct 25

<210> 26

<211> 25

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 26

gacaagcgtt agtaggcaca tatac 25

<210> 27

<211> 24

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 27

gctccaattt cccacaacat tagt 24

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 28

tcgtcaagac aagtgtggca 20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 29

cgacagacgg tgtgatggaa 20

<210> 30

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 30

acacagtcta tttcattggg gc 22

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 31

caggcactgt cacaaagggt 20

<210> 32

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 32

tcaccatctt ccaggagcga ga 22

<210> 33

<211> 21

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 33

gaaggccatg ccagtgagct t 21